+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peripherally Acting Anti-Obesity Drug Market - Global Forecast 2026-2032- Product Image
Peripherally Acting Anti-Obesity Drug Market - Global Forecast 2026-2032- Product Image
Sale

Peripherally Acting Anti-Obesity Drug Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6139323
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peripherally Acting Anti-Obesity Drug Market is projected to reach USD 3.96 Billion in 2026. It is expected to continue growing at a CAGR of 11.89%, reaching USD 7.74 Billion by 2032.

Peripherally Acting Anti-Obesity Drugs: Executive Summary

Peripherally acting anti-obesity drugs influence appetite, satiety, digestion, nutrient handling, or energy balance without relying primarily on direct central-nervous-system activity. Their development is shaped by the rising clinical burden of obesity, demand for durable weight management, safety considerations, treatment adherence, and integration with nutrition and physical-activity programs. Evaluation should consider clinical outcomes, tolerability, administration requirements, contraindications, access, and evidence across diverse patient populations.

From Short-Term Weight Loss to Long-Term Disease Management

The landscape is shifting from episodic weight-loss treatment toward chronic disease management. This change increases the importance of sustained efficacy, weight-maintenance evidence, cardiometabolic outcomes, treatment persistence, and strategies for managing discontinuation or weight regain. Additional transformation is coming from combination approaches, more selective peripheral mechanisms, improved delivery formats, and greater attention to obesity-related complications rather than body weight alone.

Artificial Intelligence Strengthens Discovery, Trial Design, and Patient Support

Artificial intelligence can accelerate target identification, compound screening, biomarker discovery, and prediction of treatment response. In clinical development, it may support patient stratification, protocol optimization, safety-signal detection, and analysis of real-world adherence. Patient-facing applications can assist with behavioral coaching and monitoring, but responsible use requires validated datasets, privacy safeguards, explainability, clinical oversight, and careful separation of predictive associations from demonstrated treatment effects.

Regional Insights: Uneven Access and Differing Care Pathways

North America is characterized by strong obesity-related research activity, specialist care capacity, and broad demand for pharmacological management, alongside persistent affordability and coverage challenges. Europe emphasizes guideline-based care, health-technology assessment, and evidence on long-term outcomes, while national reimbursement pathways vary. Asia-Pacific combines rapidly changing obesity patterns with substantial population diversity and differing regulatory systems. Latin America faces expanding clinical need alongside uneven access and healthcare-resource constraints. The Middle East is addressing high obesity prevalence through prevention, screening, and specialized treatment, while the African market requires approaches suited to diverse disease burdens, limited infrastructure, and variable medicine access.

Group Insights Across ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN reflects diverse health systems, regulatory maturity, and affordability conditions, making adaptable access and localized evidence important. BRICS countries combine large and varied patient populations with distinct manufacturing, reimbursement, and regulatory priorities. The European Union benefits from coordinated scientific and regulatory frameworks, although national funding and adoption decisions remain differentiated. G7 members generally possess advanced research and clinical infrastructure but face scrutiny over affordability, health-system capacity, and long-term value. GCC countries are investing in chronic-disease management while confronting high obesity burdens and the need for culturally appropriate care. NATO members span highly diverse healthcare environments, so common preparedness and research interests do not eliminate national differences in access or clinical practice.

Country Insights: Regulatory Diversity Shapes Adoption

The United States and Canada combine substantial clinical capacity with ongoing questions around coverage, affordability, and continuity of care. Brazil and Mexico require attention to unequal access, public-sector capacity, and regional variation. France, Germany, Italy, Spain, and the United Kingdom differ in reimbursement, guideline implementation, and health-technology assessment, despite strong clinical infrastructure. China and India present large and heterogeneous populations, varied urban-rural access, and growing needs for locally relevant evidence. Japan emphasizes an aging population, careful clinical evaluation, and integration with established medical pathways. South Korea is supported by advanced digital and healthcare infrastructure. Australia combines strong regulatory oversight with geographic access challenges. Russia presents a distinctive regulatory and healthcare environment in which availability, local evidence, and supply continuity are important considerations.

Prioritize Durable Outcomes, Access Design, and Evidence Quality

Industry leaders should prioritize mechanisms with clear peripheral rationale, clinically meaningful and durable outcomes, and transparent safety characterization. Development programs should include diverse populations, assess comorbidities and treatment persistence, and generate evidence relevant to routine care. Access planning should address affordability, reimbursement, administration burden, supply reliability, and clinician education from the outset. Partnerships with healthcare providers can improve obesity screening and follow-up, while digital tools should complement-not replace-clinical judgment. Robust pharmacovigilance, responsible AI governance, and clear communication about benefits and limitations are essential for sustainable adoption.

Research Methodology: Structured Synthesis of Clinical and Market-Relevant Evidence

This executive summary uses a structured review framework focused on the therapeutic role of peripherally acting anti-obesity drugs. The analysis considers mechanism of action, clinical development priorities, safety and tolerability, treatment delivery, patient adherence, healthcare-system integration, regulation, reimbursement, and regional variation. Geographic interpretation incorporates North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, with additional comparison across ASEAN, BRICS, the European Union, G7, GCC, and NATO. Country observations cover Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom, and the United States. Claims are framed qualitatively and avoid market estimates, market shares, forecasts, and company-specific assertions.

Success Depends on Clinical Durability and Health-System Fit

Peripherally acting anti-obesity drugs are positioned within a broader transition toward evidence-based, long-term obesity care. Their impact will depend not only on pharmacological performance but also on tolerability, persistence, affordability, equitable access, and integration with behavioral and clinical services. Leaders that combine rigorous evidence generation with responsible innovation, regionally appropriate access strategies, and strong post-treatment monitoring will be better placed to support meaningful patient and health-system outcomes.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Peripherally Acting Anti-Obesity Drug Market, by Product Type
7.1. Introduction
7.2. Glp-1 Receptor Agonist
7.3. Lipase Inhibitor
8. Peripherally Acting Anti-Obesity Drug Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
9. Peripherally Acting Anti-Obesity Drug Market, by Dosage Form
9.1. Introduction
9.2. Capsule
9.3. Suspension
9.4. Tablet
10. Peripherally Acting Anti-Obesity Drug Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Care
10.4. Hospitals
11. Peripherally Acting Anti-Obesity Drug Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Peripherally Acting Anti-Obesity Drug Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Peripherally Acting Anti-Obesity Drug Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Alvogen Iceland EHF
15.2. Amgen Inc
15.3. AstraZeneca plc
15.4. Boehringer Ingelheim International GmbH
15.5. CHEPLAPHARM Arzneimittel GmbH
15.6. Currax Pharmaceuticals LLC
15.7. Eli Lilly and Company
15.8. F. Hoffmann-La Roche Ltd
15.9. Gelesis Holdings Inc
15.10. GlaxoSmithKline plc
15.11. KVK Tech Inc
15.12. Merck & Co Inc
15.13. Norgine B.V.
15.14. Novo Nordisk A/S
15.15. Orexigen Therapeutics Inc
15.16. Pfizer Inc
15.17. Rhythm Pharmaceuticals Inc
15.18. Sanofi S.A.
15.19. Vivus LLC
15.20. Zafgen Inc
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Peripherally Acting Anti-Obesity Drug Market, Years Considered for the Study
FIGURE 2. Global Peripherally Acting Anti-Obesity Drug Market, Research Design
FIGURE 3. Global Peripherally Acting Anti-Obesity Drug Market, Research Framework
FIGURE 4. Global Peripherally Acting Anti-Obesity Drug Market, Data Triangulation
FIGURE 5. Global Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 11. Global Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Peripherally Acting Anti-Obesity Drug Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Peripherally Acting Anti-Obesity Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Peripherally Acting Anti-Obesity Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Peripherally Acting Anti-Obesity Drug Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Peripherally Acting Anti-Obesity Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Peripherally Acting Anti-Obesity Drug Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Peripherally Acting Anti-Obesity Drug Market Segmentation & Coverage
TABLE 2. Global Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 3. Global Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Glp-1 Receptor Agonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Glp-1 Receptor Agonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Glp-1 Receptor Agonist Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Lipase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Lipase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Lipase Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 11. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 18. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Suspension Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Suspension Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Suspension Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 28. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Peripherally Acting Anti-Obesity Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 40. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 41. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 42. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 43. North America Peripherally Acting Anti-Obesity Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. North America Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 45. North America Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 46. North America Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 47. North America Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 48. Latin America Peripherally Acting Anti-Obesity Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Latin America Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 50. Latin America Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 51. Latin America Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 52. Latin America Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Europe Peripherally Acting Anti-Obesity Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Europe Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 55. Europe Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 56. Europe Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 57. Europe Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 58. Middle East Peripherally Acting Anti-Obesity Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Middle East Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 60. Middle East Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 61. Middle East Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 62. Middle East Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 63. Africa Peripherally Acting Anti-Obesity Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Africa Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 65. Africa Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 66. Africa Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 67. Africa Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 68. Global Peripherally Acting Anti-Obesity Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. ASEAN Peripherally Acting Anti-Obesity Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. ASEAN Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 71. ASEAN Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 72. ASEAN Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 73. ASEAN Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. GCC Peripherally Acting Anti-Obesity Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. GCC Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 76. GCC Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 77. GCC Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 78. GCC Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. European Union Peripherally Acting Anti-Obesity Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. European Union Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 81. European Union Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 82. European Union Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 83. European Union Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. BRICS Peripherally Acting Anti-Obesity Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. BRICS Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 86. BRICS Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 87. BRICS Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 88. BRICS Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. G7 Peripherally Acting Anti-Obesity Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. G7 Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. G7 Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 92. G7 Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 93. G7 Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. NATO Peripherally Acting Anti-Obesity Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. NATO Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 96. NATO Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 97. NATO Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 98. NATO Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Global Peripherally Acting Anti-Obesity Drug Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. United States Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 101. United States Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 102. United States Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 103. United States Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 104. United States Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Canada Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 106. Canada Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. Canada Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 108. Canada Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 109. Canada Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Mexico Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 111. Mexico Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 112. Mexico Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 113. Mexico Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 114. Mexico Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. Brazil Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 116. Brazil Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 117. Brazil Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 118. Brazil Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 119. Brazil Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. United Kingdom Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 121. United Kingdom Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 122. United Kingdom Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 123. United Kingdom Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 124. United Kingdom Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Germany Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 126. Germany Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. Germany Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 128. Germany Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 129. Germany Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. France Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 131. France Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. France Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 133. France Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 134. France Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. Russia Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 136. Russia Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 137. Russia Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 138. Russia Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 139. Russia Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. Italy Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 141. Italy Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 142. Italy Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 143. Italy Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 144. Italy Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Spain Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 146. Spain Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 147. Spain Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 148. Spain Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 149. Spain Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. China Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 151. China Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 152. China Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 153. China Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 154. China Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. India Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 156. India Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 157. India Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. India Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 159. India Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Japan Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 161. Japan Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 162. Japan Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 163. Japan Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 164. Japan Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. Australia Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 166. Australia Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 167. Australia Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 168. Australia Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 169. Australia Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. South Korea Peripherally Acting Anti-Obesity Drug Market Size, 2017-2032 (USD Million)
TABLE 171. South Korea Peripherally Acting Anti-Obesity Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 172. South Korea Peripherally Acting Anti-Obesity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 173. South Korea Peripherally Acting Anti-Obesity Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 174. South Korea Peripherally Acting Anti-Obesity Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Global Peripherally Acting Anti-Obesity Drug Market Share, by Key Player, 2025
TABLE 176. Global Peripherally Acting Anti-Obesity Drug Market, Key Experts

Companies Mentioned

  • Alvogen Iceland EHF
  • Amgen Inc
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • CHEPLAPHARM Arzneimittel GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann‑La Roche Ltd
  • Gelesis Holdings Inc
  • GlaxoSmithKline plc
  • KVK Tech Inc
  • Merck & Co Inc
  • Norgine B.V.
  • Novo Nordisk A/S
  • Orexigen Therapeutics Inc
  • Pfizer Inc
  • Rhythm Pharmaceuticals Inc
  • Sanofi S.A.
  • Vivus LLC
  • Zafgen Inc

Related Topics

Related Reports

Anti-Obesity Drugs Market by Type of Molecule, Type of Drug, Active Compound, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Distribution Channel, Geographical Regions, and Key Players - Trends and Forecast Till 2035 - Product Image

Anti-Obesity Drugs Market by Type of Molecule, Type of Drug, Active Compound, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Distribution Channel, Geographical Regions, and Key Players - Trends and Forecast Till 2035

  • Report
  • 240 Pages
  • Global
From
North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029 - Product Image

North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029

  • Report
  • 72 Pages
  • North America
From
Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032 - Product Image

Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Asia Pacific
From
Anti-Obesity Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-Obesity Drugs Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Anti-Obesity Therapeutics Market - Global Forecast 2026-2032 - Product Image

Anti-Obesity Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.